Filing Flows › Arcutis Biotherapeutics (ARQT) › ZORYVE cream 0.3% revenue
Arcutis Biotherapeutics (ARQT) ZORYVE cream 0.3% revenue by quarter
Arcutis Biotherapeutics' ZORYVE cream 0.3% revenue was $37.8M in Q3 2026 (third quarter 2026), +7% from Q2 2026. Over the last 5 quarters it ranged from $27.7M (Q2 2025) to $37.8M (Q3 2026).
| Quarter | ZORYVE cream 0.3% revenue | Q/Q | Y/Y |
|---|---|---|---|
| Q3 2026 | $37.8M | +7% | +24% |
| Q2 2026 | $35.3M | +8% | +28% |
| Q1 2026 | $32.7M | +7% | — |
| Q3 2025 | $30.5M | +10% | — |
| Q2 2025 | $27.7M | — | — |
Q3 2026 at a glance
Arcutis Biotherapeutics, Q3 2026: revenue $144M (+45% year over year), operating margin 6.6%, net earnings $8.8M, operating cash flow $18.9M. The chart follows the revenue to costs, profit and cash.
Questions
What is Arcutis Biotherapeutics' ZORYVE cream 0.3% revenue?
Arcutis Biotherapeutics' ZORYVE cream 0.3% revenue was $37.8M in Q3 2026 (third quarter 2026), +7% from Q2 2026.
How has Arcutis Biotherapeutics' ZORYVE cream 0.3% revenue changed?
Over the last 5 quarters it ranged from $27.7M (Q2 2025) to $37.8M (Q3 2026).
Q3 2026 results → · How Arcutis Biotherapeutics makes money →